NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company highlighted the absence of approved vaccines or therapies specifically targeting the virus strain, underscoring the urgent need for effective interventions.
According to the company, NV-387’s host-targeted antiviral mechanism and oral formulation could offer potential advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. The drug is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox, which could support near-term regional availability if found effective against Ebola. The company noted that the drug’s broad-spectrum activity may extend to other viral infections, positioning it as a versatile candidate for emerging infectious diseases.
NanoViricides’ lead drug candidate, NV-387, is designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as mpox/smallpox and measles. The company’s platform technology is based on proprietary nanomedicine technology licensed from TheraCour Pharma, Inc. The company holds exclusive licenses for several viral diseases, including HIV/AIDS, hepatitis B and C, rabies, herpes, influenza, dengue, Japanese encephalitis, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses.
The announcement comes as the Bundibugyo strain of Ebola continues to spread in Africa, with no specific approved vaccines or treatments available. The World Health Organization has reported outbreaks of the Bundibugyo strain in Uganda and the Democratic Republic of Congo, highlighting the need for rapid development of countermeasures. NanoViricides’ NV-387, with its oral formulation, could potentially be deployed more easily than injectable treatments, reducing the burden on healthcare systems and minimizing the risk of needle-stick injuries to healthcare workers.
Investors can find the latest news and updates relating to NNVC in the company’s newsroom at https://ibn.fm/NNVC. The full press release is available at https://ibn.fm/aSF5Z.
NanoViricides is a clinical-stage company that creates special purpose nanomaterials for antiviral therapy. Its novel nanoviricide class of drug candidates and technology are based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc. The company’s business model relies on licensing technology from TheraCour for specific application verticals of specific viruses.
The company is also developing drugs against a number of viral diseases, including oral and genital herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others. NanoViricides holds a worldwide exclusive perpetual license to the TheraCour nanomedicine technology for several drugs with specific targeting mechanisms for the treatment of human viral diseases.
